BMA BIOMEDICALS

Polyclonal Antibody to Human BRI

ITM2B

This polyclonal antibody has been developed against the amino terminal sequence of BRI protein (ITM2B), a type-II single spanning transmembrane protein found in brain and other tissues. Mutation of the BRI gene with concomitant elongation of the carboxy terminus and its cleavage by the protease furin has been shown to lead to deposition of a protein fragment that may be involved in the pathogenesis of familial British dementia. See also the related product: polyclonal antibody to human ABri, product T-1516.

TECHNICAL AND ANALYTICAL CHARACTERISTICS

Product Number:	T-1515 (Lot 02AP0805)
Clone:	Polyclonal antibody
Host species, isotype:	Chicken IgY
Quantity:	200µg
Format:	Affinity purified, liquid
	Supplied as 0.2ml solution. This stock solution contains 1mg/ml IgY, phosphate buffered saline pH 7.2 (PBS) and 0.09% sodium azide as a preservative.
Stability:	Original vial: 6 months at 4° - 8°C from date of purchase.
Applications:	Tested for immunohistochemistry (IHC).
	Approximate working dilution for IHC: Optimal dilutions should be determined by the end user.
	Suggested positive control: (pathological) brain sections
	Please see **www.bma.ch** for protocols and general information.
Immunogen:	Peptide coupled to carrier protein
Protein database:	human-Q9Y287

Selected references

Vidal, R. et al.: A stop-codon mutation in the BRI gene associated with familial British dementia. Nature **399**: 776-781 (1999)

For in vitro research only. This product contains no preservative.

©2024 BMA BIOMEDICALS, Rheinstrasse 28-32, CH-4302 Augst (Switzerland)
Phone: +41 61 811 6222, Email: info@bma.ch, www.bma.ch